Masahiro Murakami

Company: Eli Lilly & Co.

Job title: Executive Director,Senior Advisor - Medical,Diabetes & Cardiovascular

Seminars:

Reimagining Biomarkers to Illuminate the Right Patient Population & Advance Precision Medicine Impact 4:00 pm

Navigating biomarkers in cardiovascular drug development that span all modalities – genetics, peripheral proteins, lipids, inflammatory markers as well as imaging and device-derived markers De-risking cardiovascular outcome trials with early proof of concept biomarkers remains a major challenge Exploratory omic analyses in cardiovascular outcomes offer hypothesis generation for precision medicineRead more

day: Conference Day 2

Establishing Potential Endpoints in Clinical Trials to Innovate Treatment 12:00 pm

Establishing Potential Endpoints in Clinical Trials to Innovate Treatment Evaluating clinically meaningful endpoints and alternatives to invasive procedures to stimulate patient engagement in trials Assessing strategies for engaging regulatory authorities in discussions on redefining approvable endpoints Identifying easily measured and highly correlated surrogate endpoints to shorten studies and reduce sample sizeRead more

day: Conference Day 2

Establishing Potential Endpoints in Clinical Trials to Innovate Treatment 1:00 pm

Considering the significant debate surrounding the optimal endpoint for demonstrating efficacy of next generation cardiovascular therapeutics, an active discussion is essential to move forward.   Attend this workshop to evaluate the current regulation on clinical endpoints to identify the windows of opportunity for the future of precise and targeted therapeutics within the cardiovascular industry.  …Read more

day: Pre-Conference Workshop Day